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1. Introduction 
Scleroderma renal crisis (SRC) is an infrequent complication of a rare disease. To date, many 
aspects of the pathophysiology of SRC are still mysterious. Since SRC biopsies are not 
frequently encountered in practice, our understanding of the spectrum of histologic changes 
is derived from a combination of a limited personal experience and data obtained from 
several relatively small pathologic studies. 
This book chapter will be devoted to discuss the pathophysiology and the histologic 
manifestations of SRC and will cover the most important aspects of clinical and laboratory 
findings as well as treatment of SRC. 
Systemic sclerosis (SSc) is a chronic systemic autoimmune disease characterized by excess 
collagen production. According to the extent of cutaneous sclerosis, SSc can be classified as 
either diffuse cutaneous (dc) or limited cutaneous (lc) variant (Sakkas, 2005). Many studies 
have been conducted to explore the pathogenesis of SSc. Activation of T-cells, B-cells and 
macrophages have been described and linked to the development and progression of 
fibrosis (Sakkas, Chikanza, & Platsoucas, 2006). Activated T-cells, mainly T helper 
lymphocyte type-2 (TH-2), are associated with increased IL-4 and IL-13 production and 
collagen accumulation. Activated B-cells produce autoantibodies that can facilitate 
transformation of fibroblasts into more fibrotic phenotypes while activated macrophages 
can accumulate in the perivascular spaces to produce transforming growth factor-B and 
platelet derived growth factor, which can also promote fibrosis. In addition to collagen 
accumulation, endothelial cell injury appears to play a central role in the pathogenesis of 
SSc. Increased permeability of the nail fold capillaries (Bollinger, Jager, & Siegenthaler, 1986) 
and  increased endothelial apoptosis (Sgonc et al., 1996)have been described in SSc patients. 
Endothelial cell injury in SSc may be triggered by anti-endothelial antibody (Worda et al., 
2003), cytokines (Kahaleh, 2004), complement abnormalities  (Venneker, van den Hoogen, 
Boerbooms, Bos, & Asghar, 1994) and/or cellular cytotoxicity (Sgonc et al., 2000).  
Scleroderma renal crisis (SRC) can complicate the course of up to 10-20% of patients with 
SSc. SRC is most commonly encountered in patients with dcSSc; however, it can still occur 
in patients with lcSSc(Sugimoto, Sanada, & Kashiwagi, 2008; Sugimoto et al., 2006) and even 
in patients with no significant dermal sclerosis, termed systemic sclerosis sine scleroderma 
(ssSSc) (Gonzalez, Schmulbach, & Bastani, 1994). Compared to SSc, much less is known 
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about the pathophysiology of SRC. This is largely attributed to the rarity of the disease and 
the absence of acceptable animal models for SRC. However, accumulating data suggest an 
important role of antibody-mediated injury in the pathogenesis of SRC. The histologic 
picture of SRC is not entirely specific for this disease. A similar histologic picture may be 
encountered in a number of primary vascular diseases and clinical conditions that may 
present as thrombotic microangiopathy. In addition to confirming the clinical diagnosis, 
renal biopsy can help predict the clinical outcome and optimize therapy in SRC patients. 
The mortality associated with SRC has decreased because of early diagnosis and 
angiotensin-converting enzyme inhibitor therapy (Collins, Patel, Eastwood, & Bourke, 1996; 
Steen, Costantino, Shapiro, & Medsger, 1990). Kidney transplantation remains as a 
treatment option for a subset of SRC patients who develop end-stage renal failure despite 
aggressive therapy. Unfortunately, the post-transplantation outcome for these patients 
continues to be worse than that of the general renal transplant population. 
2. Clinical and laboratory features 
SRC occurs more frequently in females than males and in Caucasians compared to African 
American (Sakkas, 2005). It is also much more common in patients with dcSSc than patients 
with lcSSc. However, only 10-20% of patients with dcSSc develop SRC (Ferri et al., 2002; Steen 
& Medsger, 2000b). SRC usually occurs early in the course of SSc. Up to 75% of SRC develop 
within the first four years from the diagnosis of SSc (Steen, 1994, 2003). SRC is classically 
associated with a sudden increase in blood pressure (>150/90 mm Hg) (Mouthon et al.; Steen, 
2003). This is usually accompanied by an acute deterioration in renal function. In addition, 
such patients often complain of headache, blurred vision and dyspnea as a result of 
hypertensive encephalopathy, congestive heart failure and pulmonary edema.  Nevertheless, 
up to 10% of SRC patients present with blood pressures below malignant hypertension levels 
("normotensive SRC")(Helfrich, Banner, Steen, & Medsger, 1989; Kagan, Nissim, Green, & Bar-
Khayim, 1989). In these subjects, although blood pressure is within the normal range, it is 
commonly increased from its baseline value (Helfrich, et al., 1989; Steen, 2003). 
Thrombotic microangiopathy, characterized by thrombocytopenia, normocytic hemolytic 
anemia, elevated levels of LDH and low serum haptoglobin can be encountered in 
approximately 50% of SRC patients at clinical presentation (Penn et al., 2007; Steen, 2003; 
Walker et al., 2003). In SRC patients, serum creatinine and blood urea nitrogen (BUN) are 
consistently elevated and are usually proportional to the severity of renal involvement 
(Steen, 2003). Renin blood levels are significantly elevated, especially in patients with 
malignant hypertension (Traub et al., 1983). Urinalysis may reveal microscopic hematuria 
and mild to moderate proteinuria (usually 0.5 to 2.5 grams per 24 hours) (Mouthon, et al.; 
Steen, 2003). 
With regard to autoantibodies, ANA is detected in up to 90% of SRC patients. The pattern of 
ANA immunofluorescence is usually speckled (Penn, et al., 2007). Anti-centromere 
antibody, which is typically observed in lcSSc, has been infrequently reported in SRC 
patients (Mouthon, et al.; Steen, 2005; Teixeira et al., 2008). Some investigators even consider 
the detection of anti-centromere antibody to be protective against renal crises (Penn, et al., 
2007). Anti-topoisomerase antibody, formerly known as Scl-70 antibody, is typically 
described in dSSc patients. This antibody has been shown to have some association with 
renal involvement as well as pulmonary fibrosis and cardiac disease (Steen, Powell, & 
Medsger, 1988). Anti-RNA polymerase III antibody is seen at a high frequency in patients 
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with SSc who develop SRC (B. Nguyen, Assassi, Arnett, & Mayes; Okano, Steen, & Medsger, 
1993). Anti Th/To antibodies have been reported in some cases of SRC without pulmonary 
involvement (Gunduz, Fertig, Lucas, & Medsger, 2001) while anti-RNP3 or fibrillarin 
antibodies have a stronger association with pulmonary hypertension and skeletal muscle 
involvement than SRC (Aggarwal, Lucas, Fertig, Oddis, & Medsger, 2009).  Compared to 
other autoimmune connective tissue diseases, SRC has the worst prognosis (Ferri, et al., 
2002; LeRoy et al., 1988). Predictors of poor outcome in SRC include male gender, age above 
fifty years, cardiac disease and dcSSc with extensive skin sclerosis (higher skin score) 
(Denton, Lapadula, Mouthon, & Muller-Ladner, 2009; Teixeira, et al., 2008). Normal blood 
pressure at presentation has also been associated with a poor prognosis (Medsger, Masi, 
Rodnan, Benedek, & Robinson, 1971; Penn, et al., 2007; Teixeira, et al., 2008). Patients with 
normotensive SRC could possibly have lower activation of their renin-angiotensin system 
and therefore a lower blood pressure at presentation(Penn, et al., 2007). The poor prognosis 
observed in the latter group might be attributed to a possible delay in diagnosis and 
treatment (Haviv & Safadi, 1998; Helfrich, et al., 1989).  
3. Pathophysiology 
Despite efforts to investigate the underlying immune mechanisms, the pathophysiology of 
SRC remains incompletely understood. Injury to the vascular endothelium appears to play a 
key role in activating the pathological cascade of SRC. Endothelial injury leads to increased 
endothelial permeability, vascular edema, accumulation of mucopolysaccharide material, 
and proliferation of intimal cells. If the injury is sufficiently severe, endothelial damage can 
initiate arteriolar and arterial fibrinoid necrosis and vascular thrombosis through platelet 
activation and adhesion to the sub-endothelium (Batal, Domsic, Medsger, & Bastacky, 2010; 
Fisher & Rodnan, 1958; Steen, 2003). With time, these changes can organize leading to 
fibrointimal thickening and narrowing of the small arteries (Cannon et al., 1974; Fisher & 
Rodnan, 1958). Intimal arteritis, manifested as lymphocytic and mononuclear cell 
infiltration, is typically absent in SRC (Steen, 2003). Even though collagen overproduction 
and accumulation is well established in the skin and lung lesions of SSc patients, collagen’s 
role in early kidney lesions appears less important. Increased collagen appears later in the 
form of vascular fibrointimal and adventitial thickening or as interstitial fibrosis. The latter 
is often attributed to decreased perfusion due to chronic ischemic vasculopathy.  
Intermittent vasospasm of renal arteries, also known as renal Raynaud’s phenomenon, has 
also been proposed as a potential contributor to SRC-induced kidney injury (Cannon, et al., 
1974); Traub et al. reported an increase in the frequency of SRC in the winter suggesting 
cold-induced vasoconstriction of renal arteries (Traub, et al., 1983). Vasospasm can also 
participate in renal injury in SSc patients even in the absence of SRC. Following cold pressor 
testing, Cannon et al. demonstrated a significant reduction in renal cortical blood flow in SSc 
patients when compared to control subjects (Cannon, et al., 1974). In addition, Doppler 
studies showed increased vascular resistance in SSc patients without concurrent renal 
damage (Rivolta et al., 1996). Nevertheless, Raynaud’s phenomenon does not appear to be 
the only explanation of renal injury in SSc patients without SRC. In an autopsy-based study, 
Trostle et al. were able to show well established anatomic vascular changes in the form of 
fibrointimal thickening in SSc patients without SRC (Trostle, Helfrich, & Medsger, 1986). 
Regardless of the cause, reduction in kidney perfusion causes subsequent hyperplasia of the 
juxtaglomerular apparatus (JGA) and increased renin secretion (Stone, Tisher, Hawkins, & 
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Robinson, 1974). Kovalchik et al. (Kovalchik, Guggenheim, Silverman, Robertson, & 
Steigerwald, 1978) proposed that renin production in SSc patients may be proportional to 
the severity of vascular lesions. These authors also suggested that a substantial increment in 
plasma renin activity in response to cold pressor testing could identify SSc subjects with a 
preclinical renal involvement. However, more recent studies revealed that plasma renin 
levels are neither sensitive nor predictive for SRC. Hyperreninemia has been described in 
asymptomatic SSc patients who did not develop SRC (Mouthon, et al.). The potential 
mechanisms of kidney injury in SRC are summarized in (Figure 1). 
 
 
Abbreviation: ?, Potential strong association; ??, potential weaker association; MPS, mucopolysaccharide  
Fig. 1. Potential mechanisms of injury in scleroderma renal crisis. 
Endothelin-1 is a peptide produced mainly by endothelial cells. It has three isoforms ET-1, 
ET-2 and ET-3. ET-1 binds to ET type A and ET type B receptors on muscular and 
endothelial cells (Tirapelli et al., 2005). It modulates vascular constriction and smooth 
muscle cell proliferation (Hirata, 1989; Takuwa, Takuwa, Yanagisawa, Yamashita, & Masaki, 
1989). Accumulating data suggest that the latter might play an important role in the 
pathogenesis of scleroderma. Higher serum ET-1 levels were detected in SSc compared to 
healthy controls (Vancheeswaran et al., 1994). In kidney specimens, overexpression of ET-1 
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and ET type B receptors were described in two patients who died following SRC (Kobayashi 
et al., 1999). Mouthon et al. extended the aforementioned observations by studying the 
pattern of ET-1 expression in kidney biopsies utilizing the immunoperoxidase technique 
(Mouthon et al.). These investigators found glomerular and vascular overexpression of ET-1 
in SRC specimens. In comparison, normal kidney biopsies revealed negative ET-1 
glomerular staining and only weak vascular staining. In contrast, biopsies from patients 
with hemolytic uremic syndrome (HUS) showed increased ET-1 expression on the 
glomerular but not the vascular endothelium. ET-1 expression was largely detected in areas 
of glomerular capillary wall thickening, glomerular and vascular thrombosis, and vessels 
with either mucoid changes, onion-skin lesions, or fibrointimal thickening. Of note, ET-1 
was recently identified as one of the most up regulated endothelial transcripts in allografts 
following antibody-mediated rejection 48, 49. 
C4d is an early complement split product of the classical pathway of activation. When 
detected in the peritubular capillary of an allograft biopsy, it is very suggestive of the 
diagnosis of antibody-mediated rejection (Racusen et al., 2003). Using immunoperoxidase 
techniques, we could detect similar pattern of C4d staining in a subset of SRC patients who 
had poor renal outcome (Batal et al., 2009). Nevertheless, the presence and/or significance 
of C4d deposits in SRC should be confirmed in larger studies using the more specific 
immunofluorescence techniques. 
In summary, accumulating data suggest the contribution of antibody-mediated injury in the 
pathogenesis of SRC; First, specific autoantibodies have been associated with the 
development of SRC. Second, the detection of peritubular capillary C4d staining has been 
demonstrated in occasional patients with SRC. Third, ET-1 is overly expressed in SRC 
biopsies. 
In contrast, while the role of cytotoxicity is well accepted in SSc, cytotoxicity was not 
systematically studied in SRC. The presence of peritubular capillary and tubulointerstitial 
inflammation in some SRC biopsies suggests a possible contribution of cytotoxicity to 
kidney injury. An immunohistochemical study to look at granzyme-B+ cells in such biopsy 
in association with apoptosis of endothelial cells might be an initial step to investigate such 
possibility. 
Several factors such as pericardial effusion, arrhythmia(McWhorter & LeRoy, 1974; Satoh et 
al., 1995; Steen et al., 1984), pregnancy (Karlen & Cook, 1974), sepsis (Steen, 2003) , non 
steroidal anti-inflammatory drugs (NSAID) and cocaine(Lam & Ballou, 1992) can decrease 
renal perfusion and precipitate or aggravate SRC in SSc patients. Corticosteroids are also 
believed to trigger SRC; high dose prednisone might inhibit prostacyclin levels, increase in 
angiotensin converting enzyme (ACE) activity and subsequent vasoconstriction (Sharnoff, 
Carideo, & Stein, 1951). 
Animal models are important tools to expand our knowledge of a particular disease process. 
They offer the advantage of developing targeted therapies to diseases without placing 
patients at risk of a direct intervention. Several experimental animal models of scleroderma 
have been developed (Yamamoto). One of the better-known models is bleomycin-induced 
scleroderma. A repeated intradermal or subcutaneous injection of bleomycin into rats and 
mice leads to the development of dermal sclerosis (Mountz et al., 1983; Yamamoto; 
Yamamoto & Nishioka, 2001, 2002, 2004; Yamamoto et al., 1999; Yamamoto, Takahashi, 
Takagawa, Katayama, & Nishioka, 1999). The latter is microscopically characterized by the 
deposition of thick collagen bundles, homogeneous acellular material, and cellular infiltrates 
of T-cells, macrophages, and mast cells. Ishikawa et al. has recently shown that the adoptive 
transfer of CD4+ T-cells from bleomycin-treated mice into untreated BALB/c nude mice 
www.intechopen.com
 Systemic Sclerosis – An Update on the Aberrant Immune System and Clinical Features 
 
182 
induced a similar pathological picture with autoantibody production (Ishikawa, Takeda, 
Okamoto, Matsuo, & Isobe, 2009). Dermal sclerosis in this animal model is generally limited 
to the areas of bleomycin-injection and sclerotic changes are not observed in fingers or 
abdominal skin. In addition to rodent animal models, UCD-200 chicken is another 
extensively studied SSc animal model. In addition to clinical manifestations, UCD-200 is one 
of the very few SSc models that display renal abnormalities. Endothelial cell apoptosis has 
been described in the kidneys of such animals. However, the histologic picture is different 
from what is typically observed in humans with SRC. In contrast to the typical thrombotic 
microangiopathic pattern of injury, the kidneys of UCD-200 chicken are characterized by the 
presence of glomerulonephritis associated with IgG deposition and thickening of the 
muscular vascular layer (Gershwin et al., 1981; V. A. Nguyen, Sgonc, Dietrich, & Wick, 
2000). From this model, one can conclude that SRC falls behind cutaneous sclerosis with 
regard to in vivo models. To date, SRC still lack a well-accepted animal model. 
Finally, one should remember that despite its importance in facilitating our understanding 
of the pathophysiology and treatment options, differences do exist between human and 
murine immune systems. The use of "humanized mouse model"(Pearson, Greiner, & Shultz, 
2008; Zhang, Meissner, Chen, & Su, 2010), a small immune compromised murine model 
possessing a functional reconstituted human immune system, might offer a potential way to 
overcome some existing frustrations in improving scleroderma treatment. 
4. Gross pathology 
Macroscopic changes observed in SRC are relatively nonspecific, since similar changes can 
be encountered in other thrombotic microangiopathic disorders. Petechial hemorrhages are 
frequently observed on the surface of the affected kidneys while cut sections commonly 
reveal small wedge shaped infarcts or, less often, larger foci of cortical necrosis (Fisher & 
Rodnan, 1958).  
5. Microscopic pathology 
5.1 Light microscopy 
In the absence of acceptable animal models, our current knowledge of the renal pathologic 
changes in SRC is largely derived from histologic assessment of kidney biopsy specimens 
performed during such crises. Autopsy materials provide another source to study the 
morphologic alterations of this disease, although the histologic changes in autopsy 
specimens often reflect a clinically severe and prolonged form of the disease typically 
associated with end stage renal failure. A complete understanding of the spectrum of 
pathologic changes in SRC is also limited by the low incidence of the disease and the fact 
that renal biopsies are not routinely performed during the crisis. Such biopsies are basically 
recommended when doubt exists about the etiology of renal dysfunction or, alternatively, to 
exclude the coexistence of other diseases. 
The histologic manifestations may vary during the course of the disease and the pathologic 
changes predominate in small vessels and arterioles rather than larger arteries. Early 
vascular changes can manifest as intimal edema and accumulation of acid 
mucopolysaccharide material (Figure 2), which is positively stained with Alcian blue or 
toluidine blue. Other early vascular changes include thrombosis (Figure 3) and/or fibrinoid 
necrosis. Onion-skin lesions develop later as a result of cellular proliferation (Figure 4). 
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Fig. 2. Intimal accumulation of mucoid material (artery on the right) with associated 
adventitial fibrosis (artery of the left) in a patient with scleroderma renal crisis. 
(Methenamine silver stain; original magnification x100) (Batal, et al., 2010). 
 
 
Fig. 3. Arterial thrombosis (middle) and glomerular ischemic collapse (lower left) in a 
patient with scleroderma renal crisis (Methenamine silver stain; original magnification x100) 
(Batal, et al., 2010) 
www.intechopen.com
 Systemic Sclerosis – An Update on the Aberrant Immune System and Clinical Features 
 
184 
 
Fig. 4. Onion skin lesion causing severe vascular narrowing in a patient with scleroderma 
renal crisis (Methenamine silver stain; original magnification x400) (Batal, et al., 2010). 
Fibrointimal sclerosis with or without adventitial fibrosis may be the result of chronic 
ongoing damage or, alternatively, can represent a manifestation of burned-out injury from a 
previous attack. Glomerular changes can be classified as acute or chronic. Acute glomerular 
changes manifests usually as endothelial swelling and glomerular capillary thrombosis 
(Figure 5). 
 
 
Fig. 5. Glomerular thrombosis in a patient with scleroderma renal crisis. Note the associated 
mild podocytic proliferation (Methenamine silver stain; original magnification x600) (Batal, 
et al., 2010). 
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Severe glomerular injury can lead to segmental glomerular fibrinoid necrosis or 
mesangiolysis. Fragmentation of red blood cells and fibrin deposits can be observed within 
the glomerular capillaries. These findings might sometime reflect a concurrent peripheral 
micro-hemolytic anemia (Salyer, Salyer, & Heptinstall, 1973). A common form of secondary 
glomerular injury is glomerular ischemic collapse due to decreased arterial perfusion. 
Glomerular ischemic collapse is characterized by wrinkling and thickening of the capillary 
walls and shrinkage of the glomerular tuft. Repetitive glomerular endothelial cell damage 
results in significant remodeling of the glomerular capillary walls, with glomerular 
basement membrane double contours (tram tracking) and a membranoproliferative pattern 
of injury. In more subtle cases, these changes can be focal and segmental, but over time and 
with more extensive injury, the remodeling becomes more complex and involves the 
majority of the glomerular capillary loops. The membranoproliferative pattern in thrombotic 
microangiopathies is usually associated with less mesangial proliferation, when compared 
to immune complex-mediated diseases with a similar pattern of injury by light microscopy. 
Endothelial cell injury, however, may result in mesangiolysis and resultant mesangial 
expansion that leads to nodular glomerulosclerosis as the process heals. 
Tubulointerstitial changes, usually occurring secondary to vasculopathy, are frequently 
manifested acutely as ischemic acute tubular injury/necrosis or, chronically, as tubular 
atrophy and interstitial fibrosis. A lymphohistiocytic interstitial inflammatory infiltrate can 
infrequently be observed. Mild leukocytic margination in the peritubular capillaries can 
occasionally be encountered. Small renal infarcts might be observed secondary to vascular 
injury. Early in the course of infarction, neutrophils accumulate at the junction between 
affected and non-affected areas while mononuclear cells predominate later. 
The overall histologic picture is that of a thrombotic microangiopathic process (Fisher & 
Rodnan, 1958; Mouthon et al., 2011). No histologic feature is absolutely pathognomonic for 
SRC. However, in contrast to hemolytic uremic syndrome/thrombotic thrombocytopenic 
purpura, small vessel changes predominate over glomerular changes in SRC. In hemolytic 
uremic syndrome, Tostivint et al. showed that thrombotic microangiopathic alterations were 
more frequently encountered in the glomeruli compared to small vessels [11/12 (92%) 
versus 4/12 (33%), p = .009] (Tostivint et al., 2002). In SRC, thrombi were more commonly 
detected in small vessels [11/17 (65%) small vessels thrombi versus 3/17 (18%) glomerular 
thrombi, P = .01] (Batal, et al., 2009). 
Small vessels in SRC may display thinning of the media and/or adventitial expansion. 
A few investigators suggest that the latter (Figure 2) is specific for SRC, but more data are 
needed to support this concept (Cannon, et al., 1974). Juxtaglomerular (JGA) hyperplasia can 
be observed in SRC and is believed to be associated with increased renin production (Stone, 
et al., 1974)(Figure 6). However, this feature is not entirely specific for SRC (Okada, 
Lertprasertsuke, & Tsutsumi, 2000), and is not a consistent finding. We detected a 
prominent JGA hyperplasia only in 12% of our SRC cases (Batal, et al., 2009). 
Finally, it should be noted that vascular pathologic changes in scleroderma patients are not 
restricted to SRC. Trostle et al. used morphometric techniques to study vascular changes in 
autopsy specimens (Trostle, et al., 1986). In the absence of SRC, Trostle et al. were able to 
demonstrate a significant increase in arterial fibrointimal thickness in dcSSc patients, and to 
a lesser extent in lcSSc patients, compared to age and sex matched controls. These 
observations might be explained by a possible existence of mild ongoing renal vascular 
injury below the threshold needed to trigger SRC. 
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Fig. 6. Prominent juxtaglomerular apparatus (middle) in a patient with scleroderma renal 
crisis (Methenamine silver stain; original magnification x400) (Batal, et al., 2010). 
5.2 Immunofluorescence microscopy studies 
Immunofluorescence microscopy studies typically reveal no evidence of an immune 
complex-mediated renal disease, unless the patient suffers from overlap syndrome. IgM 
deposition, which is frequently attributed to nonspecific entrapment, is the most frequently 
detected immunoglobulin in the glomeruli and/or blood vessels (Lapenas, Rodnan, & 
Cavallo, 1978; McCoy, Tisher, Pepe, & Cleveland, 1976; McGiven, De Boer, & Barnett, 1971). 
Similarly, complement deposits are frequently detected. Fibrin or fibrinogen deposition 
might also be observed in severely affected vessels or along the glomerular capillaries, 
usually with dull continuous reactivity. Identical findings are seen also in thrombotic 
angiopathies within other clinical settings. 
5.3 Electron microscopy 
Ultrastructural evaluation typically reveals severe endothelial cell injury. Well-formed 
electron dense deposits are not detected in SRC. However, hyaline material, which can 
sometime be difficult to distinguish from definite immune deposits, might accumulate in the 
sub-endothelium of the glomeruli and/or blood vessels (Silva & Pirani, 1988). Endothelial 
cell swelling and accumulation of sub-endothelial flocculent material and cell debris is a 
common finding in SRC (Figure 7). Injured endothelial cells detach from the underlying 
basement membrane and in most severe cases, the endothelial cells may be completely 
sloughed off and missing. As the endothelium recovers from the injury, it will re-grow the 
remodeled endocapillary surface and form a new basement membrane layer, resulting in 
double contour formation. The repair is usually irregular, resulting in complex 
asymmetrical glomerular basement membrane with projections and deposits of cellular 
debris in the expanded subendothelial space. The resultant pattern of glomerular wall injury 
is membranoproliferative in the absence of electron dense deposits. Within the expanded 
fibrointima of the small vessels, myointimal cells can also be demonstrated (Salomon, 
Lamovec, & Tchertkoff, 1978). 
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Fig. 7. Electron microscopic picture from a patient with scleroderma renal crisis. Note the 
prominent sub-endothelial  electron lucent fluffy material (Electron microscopy; original 
magnification x5600)(Batal, et al., 2010). 
6. Differential diagnosis (native kidneys) 
As alluded to in paragraph four (Microscopic Pathology), acute SRC is very difficult if not 
impossible to be differentiated from other thrombotic microangiopathies based on histologic 
examination alone. Thrombotic microangiopathy is a pathologic term that encompasses a 
number of clinical conditions that appear to be triggered by endothelial injury. In addition 
to the rare SRC, this pattern of injury includes, although it is not limited to, thrombotic 
thrombocytopenic purpura (TTP), typical and atypical HUS, preeclampsia, antiphospholipid 
antibody syndrome, drug-induced thrombotic angiopathy(chemotherapy, cocaine, 
calcineurin inhibitors), and what is known as "idiopathic malignant hypertension". 
Disseminated intravascular coagulation (DIC) also enters the differential diagnosis. The 
latter is usually characterized by diffuse cortical necrosis and widespread glomerular, 
vascular and intratubular microthrombi(Kawasaki, Hayashi, & Awai, 1987). However, 
arterial mucoid changes and fibrinoid necrosis are usually absent. DIC is very rarely 
encountered in surgical pathology samples compared to autopsy specimens. 
The differential diagnosis of chronic/burned-out SRC is broad. These cases often show signs 
of organization such as glomerular capillary double contours and glomerular scarring, and 
vascular sclerosis and fibrointimal thickening. In some cases, the aforementioned 
glomerular double contour can be associated with mesangial sclerosis and mild 
hypercellularity reminiscent to membranoproliferative glomerulonephritis pattern of 
glomerular injury. Membranoproliferative pattern of glomerular injury is typically seen in 
three types of disorders, including immune complex-mediated disorders (such as 
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autoimmune diseases and chronic infections), paraprotein and other deposition diseases 
(such as monoclonal immunoglobulin deposition disease, fibrillary glomerulonephritis, and 
immunotactoid glomerulopathy), and thrombotic microangiopathies. Immunofluorescence 
and ultrastructural studies are essential in distinguishing these three groups of disorders. 
The presence of polyclonal or monoclonal immunoglobulin deposition that show dense 
deposits with or without organized substructures, favors immune complex and other 
deposition diseases. In contrast, the absence of immunoglobulin deposition and the dull 
continuous reactivity for fibrin along the glomerular capillary loops by immunofluorescence 
studies, together with the absence of dense deposits by electron microscopy, characterize 
various forms of thrombotic microangiopathies. 
From a clinical perspective, one should remember that not all acute renal failure in SSc 
patients is due to SRC. Distinguishing SRC from crescentic GN is important since 
immunosuppressive therapy can exacerbate the former, but is used to treat the latter. The 
hallmark of crescentic GN is the presence of glomerular extracapillary proliferative lesions  
(crescents). As in non SSc patients, the most common form of crescentic GN in SSc patients 
is pauci-immune ANCA-associated GN, followed by immune complex GN (Ramaswami et 
al., 2008) and anti-glomerular basement membrane GN (Namba et al., 2008). In these cases, 
immunofluorescence studies are necessary for a correct sub classification. They are negative 
in the first; reveal granular immune complex deposits in the second, and linear glomerular 
basement membrane IgG staining in the third group of diseases. In contrast, crescents are 
typically absent in typical SRC, and if present, they are rare and very small (Kamen, Wigley, 
& Brown, 2006; Ramaswami, et al., 2008). Ischemic glomerulopathy lesions in SRC can 
sometime be accompanied by extracapillary epithelial cell proliferation, which can 
occasionally mimic a crescentic proliferative process. However, these ischemic 
“pseudocrescents” are characterized by the absence of necrotizing lesions, extracapillary 
fibrin, or glomerular basement membrane destruction. Furthermore, although each of 
crescentic glomerulonephritis and thrombotic microangiopathies can show vascular 
thrombosis and/or fibrinoid necrosis, one should remember that small vessel vasculitis/ 
inflammatory changes are frequently observed in the former but are typically absent in the 
latter. 
Lastly, in addition to confirming the diagnosis, renal biopsy may help in predicting the 
clinical outcome in SRC patients. A few studies have investigated the prognostic values of 
different histologic parameters in SRC. When expressed as binary variables 
(presence/absence), Penn et al. found that the presence of mucoid edema or vascular 
thrombosis was associated with a suboptimal renal outcome (Penn, et al., 2007). We 
extended Penn et al. observations by demonstrating that the severity and extent of acute 
vascular damage and its consequences, namely arterial thrombosis/fibrinoid changes and 
glomerular ischemic collapse, were indeed predictors of poor prognosis (Batal, et al., 2009). 
In contrast to the study by Penn et al., we could not associate mucoid changes with poor 
renal outcome. 
7. Treatment 
Before the advent of angiotensin converting enzymes (ACE) inhibitors, nephrectomy or 
dialysis were the only available treatment options for SRC (Mitnick & Feig, 1978; Traub, et 
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al., 1983). At that time, less than 10% of patients with SRC survived more than five 
months(Steen, 2003). ACE inhibitors were first introduced as a potential treatment of SRC in 
the late 1970s (Lopez-Ovejero et al., 1979). Since then, they have altered the management 
and outcome of this disease (Thurm & Alexander, 1984; Zawada et al., 1981), considerably 
increased patients' five year survival (up to 65%) (Steen, 2003) and rapidly became the first 
line of treatment of both hypertensive and normotensive SRC (Steen, 2003). Bosentan is an 
endothelin receptor blocker which is also considered a first line therapy (Dhaun, MacIntyre, 
Bellamy, & Kluth, 2009). However, Bosentan did not show any significant advantage over 
ACE inhibitors in regards to mortality and outcome (Patel et al., 2009). While angiotensin 
receptor blockers (ARBs) had promising results in animals with hypertension, clinical 
experience with these agents has not been very convincing (Siragy, de Gasparo, El-Kersh, & 
Carey, 2001). Currently, these medications are only considered in patients who cannot 
tolerate ACE inhibitors (Caskey, Thacker, Johnston, & Barnes, 1997; Mouthon, et al.; Steen, 
2003). 
In patients with SRC started on ACE inhibitors, one should aim for a blood pressure of 
120/70 mm Hg (Steen, 2003). If this is not achieved within 12 hours of initiation of therapy, 
then intravenous calcium channel blocker therapy should be considered. Conservative 
medical treatment alone can successfully control blood pressure in approximately 30-40% of 
SRC patients. These patients usually have a good prognosis. However, despite this 
aggressive therapy, a proportion of patients (~20%) die within three months of the onset of 
SRC due to multiorgan failure. Subjects in this group are often older males, presenting with 
highly elevated serum creatinine and have pre-existing cardiac conditions (Steen & 
Medsger, 2000a). In the remaining patients, the aforementioned medications fail to 
normalize blood pressure and dialysis should be initiated. Of note, patients requiring 
temporary dialysis (up to 18 months) had a five-year survival comparable to SSc patients 
who never had SRC (90%). In contrast, patients who required permanent dialysis had a 
considerably lower five-year survival (40%). A large subset of these patients fails to recover 
renal function and require renal transplantation (Penn, et al., 2007; Steen & Medsger, 2000a). 
8. Transplantation 
Transplantation should be considered when renal failure persists beyond 18 months from 
initiation of dialysis (Steen, 2003). In SRC, graft and patient survival post-transplantation is 
inferior to general renal transplant patient (Pham et al., 2005). Recurrence of scleroderma 
may participate in this poor outcome (Cheung, Gibson, Rush, Jeffery, & Karpinski, 2005). 
Post-transplant recurrence of SRC has been reported even after transplantation from a twin 
sister (Caplin, Dikman, Winston, Spiera, & Uribarri, 1999; Woodhall, McCoy, Gunnells, & 
Seigler, 1976). Pham et al. (Pham, et al., 2005) suggested that SRC recurrence occurs early in 
the post-transplantation course. However, Cheung et al. (Cheung, et al., 2005) challenged 
this view when describing a late SRC recurrence observed seven years post-transplantation. 
From a histologic perspective, establishing a diagnosis of recurrent SRC in a renal allograft 
is more difficult than in a native kidney biopsy. The differential diagnosis in this case is 
broader and includes acute antibody-mediated rejection, acute calcineurin inhibitor toxicity, 
and occasionally infections such as CMV. Any other thrombotic microangiopathic disease 
described in native kidneys can also manifest in the allograft as de novo thrombotic 
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microangiopathic process (Liptak & Ivanyi, 2006). Chronic SRC changes are even more 
challenging. Glomerular double contour resulting from SRC can be indistinguishable from 
chronic transplant glomerulopathy, which has been recognized as a histologic manifestation 
of chronic antibody-mediated rejection. Therefore, a careful clinicopathological and 
immunological correlation with serum creatinine changes, blood pressure, circulating 
donor-specific antibody, calcineurin inhibitor levels, and opportunistic infections are highly 
important to achieve a correct diagnosis. A careful assessment of C4d in allograft biopsies 
could also suggest the diagnosis of antibody-mediated rejection (Racusen, et al., 2003). 
However, one should keep in mind that a few patients with SRC might show some levels of 
peritubular capillary C4d staining while in contrast, C4d staining may be absent in some 
cases of antibody-mediated rejection. C4d negative antibody-mediated rejection cases have 
also been recently described (Haas, 2011; Sis & Halloran, 2010). 
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